Dataset Information

Integrative proteomic characterization of human lung adenocarcinoma

ABSTRACT: Genomic studies of lung adenocarcinoma (LUAD) have advanced understanding of the disease’s biology and accelerated targeted therapy. However, proteomic characteristics of LUAD remain poorly understood. We carried out comprehensive proteomic analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer associated characteristics, such as tumor-associated protein variants, distinct proteomic features, and clinical outcomes in patients of early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomic analysis gives a more comprehensive understanding on the molecular landscape of LUAD and offers the opportunity for more precise diagnosis and treatment.

ORGANISM(S): Homo Sapiens

SUBMITTER: Minjia Tan

PROVIDER: PXD020252 | iProX | Fri Jul 10 00:00:00 BST 2020

REPOSITORIES: iProX

ACCESS DATA

Publications

Integrative Proteomic Characterization of Human Lung Adenocarcinoma.

Xu Jun-Yu JY Zhang Chunchao C Wang Xiang X Zhai Linhui L Ma Yiming Y Mao Yousheng Y Qian Kun K Sun Changqing C Liu Zhiwei Z Jiang Shangwen S Wang Minghui M Feng Lin L Zhao Lei L Liu Ping P Wang Bo B Zhao Xin X Xie Hui H Yang Xiaoyun X Zhao Liyuan L Chang Yafei Y Jia Jingya J Wang Xijun X Zhang Yimin Y Wang Yaru Y Yang Yikun Y Wu Zhixiang Z Yang Longhai L Liu Bin B Zhao Teng T Ren Shengguo S Sun Aihua A Zhao Yang Y Ying Wantao W Wang Fei F Wang Guangshun G Zhang Yi Y Cheng Shujun S Qin Jun J Qian Xiaohong X Wang Yi Y Li Jing J He Fuchu F Xiao Ting T Tan Minjia M

Cell 20200701 1

Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct pro ...[more]

PMID: 32649877

Similar Datasets

Project description:Recent genomic approaches have suggested the existence of multiple distinct subtypes of medulloblastoma. We studied a large cohort of medulloblastomas to determine how many subgroups of the disease exist, how they differ, and the extent of overlap between subgroups. We determined gene expression profiles and DNA copy number aberrations for 103 primary medulloblastomas. Bioinformatic tools were used for class discovery of medulloblastoma subgroups based on the most informative genes in the dataset. Immunohistochemistry for subgroup-specific ‘signature’ genes was used to determine subgroup affiliation for 294 non-overlapping medulloblastomas on two independent tissue microarrays (TMAs). Multiple unsupervised analyses of transcriptional profiles identified four distinct, non-overlapping molecular variants: WNT, SHH, Group C, and Group D. Supervised analysis of these four subgroups revealed significant subgroup-specific demographics, histology, metastatic status, and DNA copy number aberrations. Immunohistochemistry for DKK1 (WNT), SFRP1 (SHH), NPR3 (Group C), and KCNA1 (Group D) could reliably and uniquely classify formalin fixed medulloblastomas in ~98% of cases. Group C patients (NPR3 +ve tumors) exhibited a significantly diminished progression free and overall survival irrespective of their metastatic status. Our integrative genomics approach to a large cohort of medulloblastomas has identified four disparate subgroups with distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome. Medulloblastomas can be reliably assigned to subgroups through immunohistochemistry, thereby making medulloblastoma sub-classification widely available. Future research on medulloblastoma and the development of clinical trials should take into consideration these four distinct types of medulloblastoma. A total of 103 primary medulloblastoma specimens were profiled by Affymetrix exon array and gene-level analysis was performed.

Dataset Information

Integrative proteomic characterization of human lung adenocarcinoma

Publications

Integrative Proteomic Characterization of Human Lung Adenocarcinoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure